Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 – from biology to focused remedy. Nat Rev Clin Oncol. 2021;18:152–69.
Balasubramanian SK, Azmi AS, Maciejewski J. Selective inhibition of nuclear export: a promising method within the shifting remedy paradigms for hematological neoplasms. Leukemia. 2022;36:601–12.
Nachmias B, Schimmer AD. Focusing on nuclear import and export in hematological malignancies. Leukemia. 2020;34:2875–86.
Azizian NG, Li Y. XPO1-dependent nuclear export as a goal for most cancers remedy. J Hematol Oncol. 2020;13:61.
Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization indicators: definition, operate, and interplay with importin alpha. J Biol Chem. 2007;282:5101–5.
Zhu ZC, Liu JW, Yang C, Zhao M, Xiong ZQ. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce most cancers cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Dying Dis. 2019;10:395.
Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, et al. Selective inhibitors of nuclear export block pancreatic most cancers cell proliferation and cut back tumor progress in mice. Gastroenterology. 2013;144:447–56.
Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic exercise in preclinical fashions of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161:117–27.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral Selinexor-Dexamethasone for triple-class refractory a number of myeloma. N. Engl J Med. 2019;381:727–38.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in sufferers with relapsed or refractory diffuse giant B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, section 2 trial. Lancet Haematol. 2020;7:e511–22.
Li W, Koster J, Xu H, Chen CH, Xiao T, Liu JS, et al. High quality management, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281.
Colic M, Wang G, Zimmermann M, Mascall Ok, McLaughlin M, Bertolet L, et al. Figuring out chemogenetic interactions from CRISPR screens with drugZ. Genome Med. 2019;11:52.
Lin DH, Correia AR, Cai SW, Huber FM, Jette CA, Hoelz A. Structural and purposeful evaluation of mRNA export regulation by the nuclear pore complicated. Nat Commun. 2018;9:2319.
Tieg B, Krebber H. Dbp5 – from nuclear export to translation. Biochim Biophys Acta. 2013;1829:791–8.
Nabet B, Ferguson FM, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, et al. Speedy and direct management of goal protein ranges with VHL-recruiting dTAG molecules. Nat Commun. 2020;11:4687.
Nakao F, Setoguchi Ok, Semba Y, Yamauchi T, Nogami J, Sasaki Ok, et al. Focusing on a mitochondrial E3 ubiquitin ligase complicated to beat AML cell-intrinsic Venetoclax resistance. Leukemia 2023;37:1028–38.
Walensky LD. Focusing on BAX to drug dying immediately. Nat Chem Biol. 2019;15:657–65.
Wickramasinghe VO, Laskey RA. Management of mammalian gene expression by selective mRNA export. Nat Rev Mol Cell Biol. 2015;16:431–42.
Kohler A, Damage E. Exporting RNA from the nucleus to the cytoplasm. Nat Rev Mol Cell Biol. 2007;8:761–73.
Kwanten B, Deconick T, Walker C, Wang F, Landesman Y, Daelemans D. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomed Pharmacother. 2023;160:114305.
Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003;17:1475–86.
Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E motion in tumorigenesis. Genes Dev. 2007;21:3232–7.
Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel Ok, Officer L, et al. MNK inhibition sensitizes. Most cancers Discov. 2021;11:1228–47.
Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, et al. Inhibition of XPO1 enhances cell dying induced by ABT-199 in acute myeloid leukaemia by way of Mcl-1. J Cell Mol Med. 2018;22:6099–111.
Lapalombella R, Solar Q, Williams Ok, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export present that CRM1/XPO1 is a goal in persistent lymphocytic leukemia. Blood. 2012;120:4621–34.
Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs mobile proliferation. J Cell Biol. 2006;175:415–26.
Topisirovic I, Siddiqui N, Lapointe VL, Trost M, Thibault P, Bangeranye C, et al. Molecular dissection of the eukaryotic initiation issue 4E (eIF4E) export-competent RNP. EMBO J. 2009;28:1087–98.
Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB. A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export equipment. RNA. 2017;23:927–37.
Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit managed by the TAL1 complicated in human T cell acute lymphoblastic leukemia. Most cancers Cell. 2012;22:209–21.
Tomoyasu C, Imamura T, Tomii T, Yano M, Asai D, Goto H, et al. Copy quantity abnormality of acute lymphoblastic leukemia cell strains primarily based on their genetic subtypes. Int J Hematol. 2018;108:312–8.
Sasaki Ok, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, et al. Genome-wide CRISPR-Cas9 display screen identifies rationally designed mixture therapies for CRLF2-rearranged Ph-like ALL. Blood. 2022;139:748–60.
Bernadin O, Amirache F, Girard-Gagnepain A, Moirangthem RD, Levy C, Ma Ok, et al. Baboon envelope LVs effectively transduced human grownup, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency. Blood Adv. 2019;3:461–75.
Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, et al. Genome-wide CRISPR-Cas9 display screen identifies leukemia-specific dependence on a Pre-mRNA metabolic pathway regulated by DCPS. Most cancers Cell. 2018;33:386–400.e385.
Malone CF, Dharia NV, Kugener G, Forman AB, Rothberg MV, Abdusamad M, et al. Selective modulation of a pan-essential protein as a therapeutic technique in most cancers. Most cancers Discov. 2021;11:2282–99.
